Candel Therapeutics to Spotlight Oncolytic Virus Pipeline at Upcoming Investor Conference (CADL)

Error: Response status code does not indicate success: 400 (Bad Request). About Candel Therapeutics (NASDAQ: CADL) Candel Therapeutics (NASDAQ: CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer